AACR-2025

AACR-2025
April 25-30, 2025
Chicago, IL

American Association for Cancer Research.

Explore more information for Gilead Oncology therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (3)

    Circulating tumor DNA (ctDNA) mutation analysis at baseline (BSL) and end of treatment (EOT) with sacituzumab govitecan (SG) and clinical impact on efficacy in patients (pts) with HR+/HER2- metastatic breast cancer (mBC): Biomarker results from TROPiCS-02

    • Author(s): Rugo, HS
    • trodelvy
    • Oncology
    • Poster

    Potential prognostic/predictive biomarkers for sacituzumab govitecan in EVOKE-01

    • Author(s): Garassino, MC
    • trodelvy
    • Oncology
    • Poster

    Trop-2 expression and association with efficacy in patients treated with sacituzumab govitecan + pembrolizumab +/- carboplatin in the EVOKE-02 study of non-small cell lung cancer

    • Author(s): Patel, JD
    • trodelvy
    • Oncology
    • Poster